This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (14)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Cerebrovascular Disease  • Encephalitis  • Stroke  • Alert me on articles by topic

Benefits Without Harm?

Giora Z. Feuerstein, MD; Xinkang Wang, PhD
From the Department of Cardiovascular Sciences, Dupont Pharmaceuticals Co, Wilmington, Del.

Reprints: Giora Z. Feuerstein, MD, Senior Director, Department of Cardiovascular Sciences, DuPont Pharmaceuticals Co, Experimental Station, E400/3257A, Wilmington, DE 19880-0400 (e-mail: giora.z.feuerstein@dupontpharma.com).

Arch Neurol. 2001;58:672-674.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

AT THE onset of the 21st century, stroke is the third-leading cause of death in most developed countries and the primary cardiovascular cause of death in Japan and China.¹ The health burden of the disease is staggering as loss of a productive life inflicts a heavy toll on patients, families, and society. Yet this disease has no effective therapy beyond a limited group of patients (5%) who are treated with thrombolytics, which have significant adverse effects. This situation prevails despite intense research efforts and numerous clinical trials that have attempted to develop drugs to reduce morbidity and mortality from stroke. So far, drug development efforts have targeted modulators of ion channels (Ca²⁺and Na⁺), scavengers of oxygen radicals, and antagonists of excitotoxic neurotransmitters (primarily glutamate and glycine receptors). However, clinical trials with modulators of these targets have failed so far because of . . . [Full Text of this Article]

RELATED ARTICLES

Inflammation After Stroke: Is It Harmful?
Gregory J. del Zoppo, Kyra J. Becker, and John M. Hallenbeck
Arch Neurol. 2001;58(4):669-672.
EXTRACT | FULL TEXT  

The Potential for Harm or Benefit From Inflammatory Processes in Stroke
John N. Whitaker
Arch Neurol. 2001;58(4):674.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Microglia Cells Protect Neurons by Direct Engulfment of Invading Neutrophil Granulocytes: A New Mechanism of CNS Immune Privilege
Neumann et al.
J. Neurosci. 2008;28:5965-5975.
ABSTRACT | FULL TEXT  

Selective Ablation of Proliferating Microglial Cells Exacerbates Ischemic Injury in the Brain
Lalancette-Hebert et al.
J. Neurosci. 2007;27:2596-2605.
ABSTRACT | FULL TEXT  

{gamma}-Amino Butyric Acid Type B Receptors Stimulate Neutrophil Chemotaxis during Ischemia-Reperfusion
Rane et al.
J. Immunol. 2005;174:7242-7249.
ABSTRACT | FULL TEXT